Imovax (Td) Adult

Diphtheria toxoid and tetanus toxoid, the active ingredients in Imovax (Td) Adult, are vaccine components presented as an injectable solution for intramuscular or subcutaneous use. They stimulate protective immunity and are administered as booster immunizations against tetanus and diphtheria in adults.

GNH USA supplies Imovax (Td) Adult as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides cold‑chain logistics to ensure product integrity during transport. Customers receive regulatory documentation and support for import compliance.

Imovax (Td) Adult is a tetanus‑diphtheria toxoid vaccine used for booster immunization in the adult population. - Tetanus: restores protective antibody levels against tetanus toxin in adults. - Diphtheria: restores protective antibody levels against diphtheria toxin in adults. - Combined Td booster: provides renewed immunity to both tetanus and diphtheria in the adult population. - Travel preparation: ensures immunity for adults traveling to regions with higher tetanus or diphtheria risk.

Imovax (Td) Adult may be associated with local and systemic reactions following injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema around the injection area. - Low‑grade fever: transient temperature rise, usually below 38.5 °C. - Headache: mild headache occurring within 24 hours post‑vaccination. - Fatigue: temporary feeling of tiredness or weakness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder characterized by muscle weakness. - High fever: temperature above 39 °C persisting more than 48 hours. - Seizures: convulsive episodes occurring shortly after vaccination. - Severe local reaction: extensive swelling or necrosis at injection site.

Before administering Imovax (Td) Adult, healthcare professionals should consider several precautionary measures. - Contraindication: avoid use in individuals with documented severe allergic reaction to any vaccine component. - Pregnancy: defer vaccination unless the benefit outweighs potential risk; consult obstetric guidance. - Immunocompromised: assess risk, as response may be reduced; vaccine is not live. - Acute illness: postpone vaccination if the patient has moderate or severe febrile illness. - Anticoagulant therapy: apply pressure post‑injection to minimize bleeding or hematoma. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax (Td) Adult may interact with certain medications or medical conditions; awareness of these interactions helps ensure safe administration.

Major Interactions (Avoid): - Immunoglobulin therapy: may neutralize vaccine antigens, reducing immunogenicity. - Blood products: concurrent administration can impair antibody response.

Moderate Interactions (Monitor Closely): - Anticoagulants: increase risk of injection‑site bleeding; monitor for hematoma. - Corticosteroids: high‑dose therapy may diminish vaccine efficacy. - Antipyretics: prophylactic use may mask fever, but generally acceptable.